Ativan injection for anxiety relief and status epilepticus treatment

Ativan injection contains lorazepam, a benzodiazepine used for its sedative, anxiolytic, and anticonvulsant effects. It is supplied for intravenous and intramuscular use in adults and acts quickly to relieve anxiety and manage seizures, including status epilepticus.

Ativan injection is approved for the following uses in adults:

• Relief of preoperative anxiety and sedation before surgery.
• Treatment of status epilepticus (a prolonged seizure emergency condition).

It is not intended for use in neonates and should only be used intermittently as directed.

lorazepam

Lorazepam acts by binding to specific benzodiazepine receptor sites on the gamma-aminobutyric acid (GABA) receptor complex in the brain. This enhances the effect of GABA, a neurotransmitter that inhibits nerve activity, leading to sedation, reduced anxiety, and anticonvulsant effects. The degree of receptor occupancy correlates with the intensity of these effects.

Adults: Typical doses for intravenous or intramuscular administration range from 2 mg to 4 mg, depending on the indication.

For status epilepticus, initial intravenous doses are 2 mg, with an optional additional 2 mg if needed. Some patients may receive up to 4 mg initially or further doses if seizures persist.

The sedative and anxiolytic effects usually last 6 to 8 hours.

Important administration notes:

• Use only for intermittent use as directed; avoid frequent or prolonged dosing.
• Not for use in neonates.
• Contains benzyl alcohol preservative, which is contraindicated in neonates.

Use is contraindicated in neonates due to benzyl alcohol content and altered clearance.

Risks with opioids: Concurrent use of Ativan with opioids can cause profound sedation, respiratory depression, coma, or death. Prescribe together only when alternatives are inadequate, and monitor closely.

Abuse and dependence: Lorazepam carries risks of abuse, misuse, and addiction, which can lead to overdose or death, particularly when combined with other substances like alcohol.

Withdrawal risk: Prolonged or frequent use can lead to physical dependence. Abrupt stopping or rapid dose reduction may cause life-threatening withdrawal symptoms; taper doses gradually if discontinuing in such scenarios.

Respiratory effects: At recommended doses, lorazepam does not generally depress respiratory response to carbon dioxide, but overdose and excessive sedation can cause upper airway obstruction and respiratory depression.

Not for pediatric neonates: Unsafe due to benzyl alcohol preservative and altered pharmacokinetics in neonates.

Common effects: Sedation, drowsiness, unsteadiness, or lack of recall of events related to treatment, which generally lasts 6 to 8 hours. Some may experience prolonged sleepiness and impaired coordination.

Serious effects: Rare cases of respiratory depression and airway obstruction have been reported, typically with overdose or excessive dosing.

Opioids: Combined use increases risk of severe sedation and respiratory depression.

Other CNS depressants: May enhance sedative effects of alcohol and other nervous system depressants.

Overdose may result in excessive sedation, respiratory depression, coma, and loss of airway reflexes. Management involves supportive care and monitoring for respiratory and cardiovascular function.

Store according to the product's official instructions; specific storage conditions are not detailed in the provided text.